DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Efficacy and safety of topical tazarotene: a review.

Author(s): Talpur R, Cox K, Duvic M

Affiliation(s): University of Texas, MD Anderson Cancer Center, Department of Dermatology, Houston, Texas, USA. rtalpur@mdanderson.org

Publication date & source: 2009-02, Expert Opin Drug Metab Toxicol., 5(2):195-210.

Publication type: Review

BACKGROUND: Tazarotene (Tazorac, Avage, Allergan, Inc., Irvine, CA, USA) is a synthetic retinoic acid receptor- betagamma topical retinoid approved for the treatment of plaque psoriasis and acne vulgaris. OBJECTIVES: To review a decade of experience using tazarotene as a monotherapy or as combination therapy for approved and other indications: acne, psoriasis, photoaging, basal cell carcinomas and various keratinization disorders. METHODS: We reviewed the published literature available on PubMed for safety and efficacy of topical tazarotene gel or cream preparations. RESULTS/CONCLUSIONS: Tazarotene, in both gel and cream formulations, has been used both as monotherapy and as an adjuvant therapy. For psoriasis it has been combined with steroids, calcipotriene and phototherapy, and for acne, with antibiotics. Tazarotene has been shown to upregulate the tumor suppressor, tazarotene induced gene 3, which is overexpressed in psoriasis and skin cancer. Adverse effects are limited to mild to moderate local irritation and erythema as seen with the 'retinization period' of other topical retinoid therapies. Daily application of tazarotene is effective with sustained benefits and limited local side effects.

Page last updated: 2010-10-05

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017